文献速递眼底病与葡萄膜炎

美国糖尿病黄斑水肿抗VEGF治疗启动时的种族、民族和保险差异

Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in the US.
PubMed 文献 · Ophthalmology · 2021-03-11

结果显示,医疗保险和商业保险患者基线视力优于医疗补助患者,白人和非西班牙裔患者视力优于对应群体,黑人和西班牙裔患者基线糖尿病视网膜病变严重程度更差。结论提示抗VEGF治疗启动时存在民族和保险相关的差异。

要点

  • 医疗保险和商业保险患者基线视力优于医疗补助患者。
  • 白人和非西班牙裔患者基线视力优于对应群体。
  • 黑人和西班牙裔患者基线糖尿病视网膜病变严重程度更差。

核心结论

  • 因糖尿病黄斑水肿启动抗VEGF治疗时存在民族和保险相关的视力及疾病严重程度差异。
  • 公共卫生措施可能改善治疗的及时启动。

研究设计与样本

  • 采用多变量回归分析种族、民族、保险状态和地理位置与基线特征的关系。

主要发现

  • 医疗保险和商业保险患者基线视力分别比医疗补助患者中位数高2.31和4.17个ETDRS字母(P<0.01)。
  • 白人和非西班牙裔患者基线视力分别比对应群体中位数高0.68和2.53个ETDRS字母(P<0.01)。
  • 黑人和西班牙裔患者基线糖尿病视网膜病变严重程度分别比白人和非西班牙裔患者更差(比值比1.23和1.71,P<0.01)。

临床怎么用

  • 临床中应关注医疗补助、黑人和西班牙裔糖尿病黄斑水肿患者,促进抗VEGF治疗的及时启动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study characterizes the association of risk factors including race, ethnicity, and insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in patients initiating treatment with anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). DESIGN: Retrospective, cross-sectional study. PARTICIPANTS: The Academy Intelligent Research in Sight (IRIS) Registry database was queried for patients who initiated anti-VEGF injection treatment for DME between 2012 and 2020 (n = 203 707). METHODS: Multivariate regression analyses were conducted to understand how race, ethnicity, insurance status, and geographic location were associated with baseline features. MAIN OUTCOME MEASURES: Visual acuity and DR severity. RESULTS: Patients on Medicare and private insurance presented with higher baseline VA compared with patients on Medicaid (median of 2.31 and 4.17 greater Early Treatment Diabetic Retinopathy Scale [ETDRS] letters, respectively P < 0.01). White and non-Hispanic patients presented with better VA compared with their counterparts (median of 0.68 and 2.53 greater ETDRS letters, respectively; P < 0.01). Black and Hispanic patients presented with a worse baseline DR severity compared with White and non-Hispanic patients (odds ratio, 1.23 and 1.71, respectively; P < 0.01). CONCLUSIONS: There are ethnic and insurance-based disparities in VA and disease severity upon initiation of anti-VEGF therapy for DME treatment. Public health initiatives could improve timely initiation of treatment.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Malhotra NA, Greenlee TE, Iyer AI, et al. Racial, Ethnic, and Insurance-Based Disparities Upon Initiation of Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in the US. Ophthalmology. 2021. PMID: 33716048. doi:10.1016/j.ophtha.2021.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。